QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
OTCMKTS:IPSEY

Ipsen (IPSEY) Stock Price, News & Analysis

$29.41
-0.39 (-1.31%)
(As of 03/27/2024 ET)
Today's Range
$29.41
$29.54
50-Day Range
$27.50
$29.80
52-Week Range
$26.97
$34.34
Volume
674 shs
Average Volume
905 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
0.78%
Price Target
N/A
IPSEY stock logo

About Ipsen Stock (OTCMKTS:IPSEY)

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

IPSEY Stock Price History

IPSEY Stock News Headlines

Investors Alert: The Next Big Thing in Weight Loss
History shows biotech breakthroughs like this can turn small investments into staggering fortunes for those with the foresight to get in early. I've isolated the small company behind it all...
Ipsen Shares Fall After Forecast of Lower Margin
Investors Alert: The Next Big Thing in Weight Loss
History shows biotech breakthroughs like this can turn small investments into staggering fortunes for those with the foresight to get in early. I've isolated the small company behind it all...
Biotech Stocks Facing FDA Decision In February 2024
Ipsen Says Health Canada Approved Bylvay To Treat Pruritus Due To PFIC
Ipsen 9-month Sales Up
Ipsen Pharma: Ipsen updates on QM-1114 regulatory process
Ipsen updates on QM-1114 regulatory process
Laura Ipsen
See More Headlines
Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
OTCMKTS:IPSEY
CIK
N/A
Employees
5,300
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.58 billion
Cash Flow
$3.46 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.91
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. David Loew (Age 57)
    MD, CEO & Director
    Comp: $2.41M
  • Mr. Aymeric Le Chatelier (Age 55)
    Executive VP & CFO
    Comp: $794.14k
  • Dr. Aidan Murphy Ph.D. (Age 58)
    Executive VP and Head of Technical Operations
  • Mr. Craig Marks
    Vice-President of Investor Relations
  • Mr. Francois Garnier (Age 62)
    Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer
  • Ms. Gwenan White
    Executive VP and Head of Communications, Public Affairs & Sustainability
  • Mr. Regis Mulot (Age 58)
    Executive VP & Chief Human Resources Officer
  • Ms. Dominique Bery (Age 53)
    Head of Nordics & Baltics
  • Mr. Bartosz Bednarz D.D.S.
    Executive VP and Head of Global Product & Portfolio Strategy
  • Mr. Philippe Lopes-Fernandes CBO
    Executive VP & Chief Business Officer

IPSEY Stock Analysis - Frequently Asked Questions

Should I buy or sell Ipsen stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IPSEY shares.
View IPSEY analyst ratings
or view top-rated stocks.

How have IPSEY shares performed in 2024?

Ipsen's stock was trading at $29.48 on January 1st, 2024. Since then, IPSEY shares have decreased by 0.2% and is now trading at $29.41.
View the best growth stocks for 2024 here
.

Are investors shorting Ipsen?

Ipsen saw a decline in short interest in March. As of March 15th, there was short interest totaling 400 shares, a decline of 63.6% from the February 29th total of 1,100 shares. Based on an average trading volume of 2,200 shares, the short-interest ratio is presently 0.2 days.
View Ipsen's Short Interest
.

How often does Ipsen pay dividends? What is the dividend yield for Ipsen?

Ipsen declared a dividend on Thursday, June 1st. Investors of record on Monday, June 5th will be given a dividend of $0.2337 per share on Tuesday, June 27th. This represents a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, June 2nd. This is an increase from the stock's previous dividend of $0.23.
Read our dividend analysis for IPSEY
.

Is Ipsen a good dividend stock?

Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.23 per share and currently has a dividend yield of 0.77%.
Read our dividend analysis for IPSEY.

How do I buy shares of Ipsen?

Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IPSEY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners